PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.43%
Revenue growth 1.25-1.5x 3088.T's 4.11%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
-1.29%
Negative gross profit growth while 3088.T is at 3.11%. Joel Greenblatt would examine cost competitiveness or demand decline.
1.44%
EBIT growth below 50% of 3088.T's 30.05%. Michael Burry would suspect deeper competitive or cost structure issues.
-18.28%
Negative operating income growth while 3088.T is at 33.23%. Joel Greenblatt would press for urgent turnaround measures.
5.98%
Net income growth under 50% of 3088.T's 31.84%. Michael Burry would suspect the firm is falling well behind a key competitor.
5.99%
EPS growth under 50% of 3088.T's 33.50%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
5.99%
Diluted EPS growth under 50% of 3088.T's 33.50%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.31%
10Y revenue/share CAGR at 50-75% of 3088.T's 24.71%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
2.26%
5Y revenue/share CAGR under 50% of 3088.T's 27.61%. Michael Burry would suspect a significant competitive gap or product weakness.
-26.41%
Negative 3Y CAGR while 3088.T stands at 14.46%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
100.00%
Positive long-term OCF/share growth while 3088.T is negative. John Neff would see a structural advantage in sustained cash generation.
100.00%
Positive OCF/share growth while 3088.T is negative. John Neff might see a comparative advantage in operational cash viability.
No Data
No Data available this quarter, please select a different quarter.
108.41%
Net income/share CAGR above 1.5x 3088.T's 54.12% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
54.75%
5Y net income/share CAGR similar to 3088.T's 54.54%. Walter Schloss might see both on parallel mid-term trajectories.
-17.52%
Negative 3Y CAGR while 3088.T is 32.56%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
63.41%
10Y equity/share CAGR in line with 3088.T's 61.27%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
33.94%
5Y equity/share CAGR at 50-75% of 3088.T's 49.37%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-10.40%
Negative 3Y equity/share growth while 3088.T is at 36.90%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.52%
Inventory growth well above 3088.T's 3.97%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.64%
Asset growth above 1.5x 3088.T's 3.83%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.81%
BV/share growth above 1.5x 3088.T's 1.34%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
66.15%
Debt shrinking faster vs. 3088.T's 12141.46%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
3.57%
We expand SG&A while 3088.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.